Earnings Preview For Capricor Therapeutics

Capricor Therapeutics CAPR announces its next round of earnings Wednesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Wall Street analysts see Capricor Therapeutics reporting a loss of 10 cents per share on revenue of $630,000.

Capricor Therapeutics EPS in the same period a year ago came in at a loss of 21 cents. Revenue was $906,000. The analyst consensus estimate would represent a 52.38 increase in the company's earnings. Sales would have fallen 30.53 percent from the same quarter last year.

The company's reported EPS has stacked up against analyst estimates in the past like this:

 

Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.19 -0.18 -0.15 -0.3
EPS Actual -0.12 -0.16 -0.17 -0.21

 

Stock Performance

Over the last 52-week period, shares are down 38.7 percent. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release.

Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on Capricor Therapeutics stock is a Buy. The validity of this rating has maintained conviction over the past 90 days.

Conference Call

Don't be surprised to see the stock move on comments made during its conference call. Capricor Therapeutics' Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here: http://capricor.com/news/events/

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPreviewsTrading IdeasEarnings Previews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...